Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for treating locally advanced or metastatic, triple negative, PD-L1 positive breast cancer that has not been previously treated.
Following on from information provided to NICE by the company in November 2020 the appraisal of Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 2705
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 December 2022 | Discontinued. Following on from information provided to NICE by the company in November 2020 the appraisal of Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 17 November 2021 | Expected publication |
| 27 November 2020 | Note added to the project documents |
| 27 November 2020 | Suspended. Topic is suspended |
| 06 July 2020 | Note added to the project documents |
| 29 May 2020 - 29 June 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 10 January 2020 | In progress. Referred September 23 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual